TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06754930
Drug: SHR-1826
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1826 for injection.
Study: NCT06754930
Drug: SHR-1316
Normalized name: Immunoglobulin G4 (52-glycine, 57-phenylalanine, 227-proline, 233-alanine, 234-alanine, 446-alanine), anti-(human programmed death-ligand 1) (human-mus musculus monoclonal SHR-1316 .gamma.4-chain) fusion protein with peptide linker ((ggggs)4g) fusion protein with 20-136-type II transforming growth factor .beta. receptor (human isoform 1), disulfide with (85-glutamic acid) human-mus musculus monoclonal SHR-1316 .kappa.-chain, dimer
DrugBank: Retlirafusp alfa (DB17517)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1316 for injection.
Study: NCT06754930
Drug: SHR-9839
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-9839 for injection.
Study: NCT06754930
Drug: SHR-8068
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-8068 for injection.
Study: NCT06754930
Drug: Ametinib mesylate
Normalized name: Trametinib
DrugBank: Refametinib (DB06309)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ametinib mesylate.
Study: NCT06754930
Drug: BP-102
Normalized name: SBC-102
DrugBank: Sebelipase alfa (DB11563)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BP-102 for injection.
Study: NCT06754930
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin for injection.
Study: NCT06506916
Drug: bimekizumab
Normalized name: bimekizumab
DrugBank: Bimekizumab (DB12917)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Study participants receive bimekizumab (BKZ) administered subcutaneously at pre-specified timepoints during study.
Study: NCT06763731
Drug: Systane COMPLETE
Normalized name: Systane Complete Preservative Free
DrugBank: Propylene glycol (DB01839)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preop dry eye management using Systane COMPLETE can help to optimize the ocular surface.
Study: NCT06758882
Drug: Apalutamide
Normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: administration of non steroid androgenic receptor inhibitors plus androgen deprivation therapy
Study: NCT06762041
Drug: Metformin treatment
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Interested subjects with autism are treated with metformin with a standard dosage
Study: NCT06759558
Drug: Zuranolone
Normalized name: Zuranolone
DrugBank: Zuranolone (DB15490)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zuranolone is a neuroactive steroid that works by modulating the activity of the gamma-aminobutyric acid (GABA) receptor in the brain.
Study: NCT06746701
Drug: Peg-IFNα-2b combined with NA
Normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: From baseline day 1, take NA orally once daily until the drug can be discontinued. Concurrently, combine with Peg-IFN α-2b 180μg, administered subcutaneously once a week for 48-96 weeks (if the surface antigen is not converted to negative at week 48, continue Peg-IFN α-2b treatment, but the course of treatment should not exceed 96 weeks). Discontinue Peg-IFN α-2b (while maintaining continuous oral administration of NA), and continue taking NA orally.
Study: NCT06758739
Drug: Intralesional Steroid Injection
Normalized name: flumethasone
DrugBank: Flumethasone (DB00663)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional Steroid Injection (1cc), one per week, will be administered in the fibrous bands wherever formed in the oral cavity. Patient recovery progress will be monitored on monthly basis for three months.
Study: NCT06759636
Drug: Romiplostim N01
Normalized name: Romiplostim
DrugBank: Romiplostim (DB05332)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3.0 µg/kg, subcutaneous injection, once a week. Afterwards, refer to the platelet count evaluated during the visit before the next dosing cycle: ① If the platelet count is less than 50×10\^9/L, increase by 1-2μg/kg once a week; ② If the platelet count is between 50-99×10\^9/L, increase by 1μg/kg once a week. According to platelet count and symptoms, investigators can adjust the dosage to the maximum dosage of 10μg/kg once a week.
Study: NCT06759636
Drug: Recombinant Human Interleukin-11 (rhIL-11)
Normalized name: Recombinant interleukin-11
DrugBank: Oprelvekin (DB00038)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25-50μg/kg, subcutaneous injection, once a day
Study: NCT06747936
Drug: AD-2281
Normalized name: Stahist AD
DrugBank: Pseudoephedrine (DB00852)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PO, Once daily, 8weeks
Study: NCT06747936
Drug: AD-2282
Normalized name: Stahist AD
DrugBank: Pseudoephedrine (DB00852)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PO, Once daily, 8weeks
Study: NCT06774274
Drug: Ketamine infusion
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A 10% ketamine solution will be prepared in a 250 cc bag of 0.9% saline (1 mg/cc) using 5 cc from a vial of ketamine that has a concentration of 50 mg/cc. The infusion will be initiated at the time of surgical site closure and will proceed as follows: a bolus of 0.35 cc/kg (equivalent to 0.35 mg/kg) will be administered, followed by a continuous infusion of 0.1 cc/kg/h (equivalent to 0.1 mg/kg/h) for up to 48 hours postoperatively.~Patients in this group will have access to a PCA pump with morphine for analgesic rescue and to monitor daily opioid consumption.
Study: NCT06774274
Drug: PCA Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A mixture of 5% ketamine and 5% morphine will be prepared in a 100 cc bag of 0.9% saline. This will be achieved by using 1 cc of a ketamine vial (50 mg/cc) and 5 cc of a morphine ampule (10 mg/cc). This results in a final concentration of 0.5 mg of ketamine and 0.5 mg of morphine per cc in the 100 cc saline bag.~The pump settings will be configured as follows:~* PCA (Patient-Controlled Analgesia) dose: 2 cc (which delivers 1 mg of ketamine and 1 mg of morphine)~* Lockout interval: 6 minutes~* Maximum dose limit: 15 doses over a 4-hour period~The pump will be available for patient use for up to 48 hours postoperatively.
Study: NCT06740370
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: (12 mg (body weight ≥60 kg) , 8 mg (body weight \<60 kg) orally once a day
Study: NCT06740370
Drug: PD-1 Inhibitors
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab (200mg intravenously every 3 weeks), Sintilimab (200mg intravenously every 3 weeks), Camrelizumab (200mg intravenously every 3 weeks)
Study: NCT05681442
Drug: AG infusion most 1 dose
Normalized name: coagulation factor IX recombinant immunoglobulin G1 fusion protein 1 UNT [Alprolix]
DrugBank: Coagulation Factor IX (Recombinant) (DB00100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG infusion most 1 dose (AMT group )
Study: NCT06762600
Drug: HRS-4729 injection
Normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-4729 injection
Study: NCT06751784
Drug: Fampridine SR
Normalized name: FAMPRIDINE
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active study medication consists of 15 tablets of fampridine SR 10 mg formulated for oral administration taken in the morning and evening 12 h apart without food. Tablets must be administered whole.
Study: NCT06772779
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single oral dose
Study: NCT06772779
Drug: Enlicitide Decanoate
Normalized name: decanoic acid
DrugBank: Capric acid (DB03600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose
Study: NCT06772779
Drug: Lisinopril
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single oral dose
Study: NCT05171179
Drug: Exparel
Normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exparel is a sterile, non-pyrogenic white to off-white preservative-free aqueous suspension of multivesicular liposomes (DepoFoam® drug delivery system) containing bupivacaine. Bupivacaine is present at a concentration of 13.3 mg/mL. After injection of Exparel, bupivacaine is released from the multivesicular liposomes over a period of time.
Study: NCT05171179
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is an anesthetic delivered during breast reconstruction surgery that will be given to participants in arms 2 and 3.
Study: NCT05171179
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is an anesthetic delivered during breast reconstruction surgery that will be given to participants in arm 1.
Study: NCT06752590
Drug: ONO-1110
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-1110 tablets once a day
Study: NCT06754059
Drug: Pyrotinib
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this study, after at least 4 cycles of taxoid chemotherapy combined with trastuzumab ± pertuzumab, the evaluation result reached SD, CR or PR, and capecitabine combined with pyrotinib + trastuzumab was given successively in the later period (capecitabine was used for 4-6 cycles
Study: NCT06763159
Drug: HS-20124 (Phase Ia：Dose escalation )
Normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive HS-20124 in 21 day dosing cycles. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
Study: NCT06763159
Drug: HS-20124 (Phase Ib: Dose expansion)
Normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive HS-20124 in 21 day dosing cycles. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
Study: NCT06765109
Drug: Neladalkib (NVL-655)
Normalized name: NVL-655
DrugBank: NVL-655 (DB18682)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet of Neladalkib (NVL-655)
Study: NCT06765109
Drug: Alectinib
Normalized name: Alectinib
DrugBank: Alectinib (DB11363)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral capsule of alectinib
Study: NCT06767085
Drug: Lidocaine-Prilocaine Topical
Normalized name: lidocaine-prilocaine topical
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lidocaine-prilocaine spray on the cervix and cervical canal 5-7 minutes prior to the procedure
Study: NCT05268237
Drug: Liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sublingual or subcutaneous liraglutide
Study: NCT06763315
Drug: Selumetinib
Normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use of the internationally recommended standard dose and low dose of the same drug
Study: NCT06740188
Drug: Citalopram hydrobromide combined with zolpidem
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the control group was given citalopram hydrobromide combined with zolpidem
Study: NCT06662123
Drug: Anifrolumab
Normalized name: ANIFROLUMAB
DrugBank: Anifrolumab (DB11976)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive a single SC or IV dose of anifrolumab at day 1
Study: NCT06191315
Drug: Dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form: Injection solution Route of administration: Subcutaneous
Study: NCT06754098
Drug: Doxecitine and Doxribtimine
Normalized name: Doxecitine
DrugBank: 2'-Deoxycytidine (DB02594)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A combination of doxecitine and doxribtimine is administered orally in 3 equal doses given approximately 6 to 8 hours apart .Dose will be increased if the tolerability profile is good.
Study: NCT06516887
Drug: bemcentinib
Normalized name: Bemcentinib
DrugBank: Bemcentinib (DB12411)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bemcentinib has been investigated in a phase I/II clinical trials for solid tumors. Phase I and II clinical studies of BGB324 are ongoing in non-small cell carcinoma, in which combinations with other agents such as Phase I study of docetaxel (NCT02922777), erlotinib (NCT02424617), and pembrolizumab (NCT03184571) are also being investigated. In a phase I dose escalation study of bemcentinib in combination with docetaxel study, patients with treatment naïve, advanced lung adenocarcinoma receive docetaxel 75 mg/m2 given IV every 21 days in combination with bemcentinib. Bemcentinib dose will be escalated in a standard 3+3 fashion until a maximum tolerated dose is determined.
Study: NCT06516887
Drug: pacritinib
Normalized name: Pacritinib
DrugBank: Pacritinib (DB11697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For use in clinical studies as an oral agent, pacritinib is supplied as size #0 hard gelatin capsules with gray bodies and scarlet caps. Capsules contain 100 mg pacritinib (free base) and the following inactive ingredients: microcrystalline cellulose NF, polyethylene glycol 8000 NF, and magnesium stearate NF. The capsule gelatin is bovine derived. Pharmacies at investigational sites will receive subject-specific bottles containing 120 capsules packaged in 200 mL high-density polyethylene bottles with child-resistant closures.
Study: NCT06372145
Drug: Tolebrutinib
Normalized name: Tolebrutinib
DrugBank: Tolebrutinib (DB18715)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Tablet-Route of administration:oral
Study: NCT06372145
Drug: Teriflunomide
Normalized name: Teriflunomide
DrugBank: Teriflunomide (DB08880)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical form:Tablet-Route of administration:oral
Study: NCT06738251
Drug: SHR-A2102 for Injection
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-A2102 for Injection.
Study: NCT06738251
Drug: Docetaxel Injection
Normalized name: docetaxel Injection
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel Injection.
Study: NCT06738251
Drug: Paclitaxel Injection
Normalized name: paclitaxel Injection
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel Injection.
Study: NCT06738251
Drug: Gemcitabine Hydrochloride for Injection
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine Hydrochloride for Injection.
Study: NCT06738251
Drug: Pemetrexed Disodium for Injection
Normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed Disodium for Injection.
Study: NCT05973851
Drug: Esketamine Nasal Product
Normalized name: esketamine Nasal Product
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See arm description
Study: NCT05973851
Drug: Ketamine Hydrochloride
Normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See arm description
Study: NCT05973851
Drug: Esketamine hydrochloride
Normalized name: esketamine hydrochloride
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: See arm description
Study: NCT06794554
Drug: Rezafungin Acetate
Normalized name: rezafungin acetate
DrugBank: Rezafungin (DB16310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV with a 400 mg loading dose on Day 1 of Week 1, followed by 200 mg once weekly, for a total of 26 doses (6 months).
Study: NCT05043077
Drug: Microdrop administration of phenylephrine 1.67% and tropicamide 0.33%
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 drop (6.5 μL) for 3 doses with 5-minute intervals
Study: NCT05043077
Drug: Standard drop administration of phenylephrine 1.67% and tropicamide 0.33%
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 drop (28-34 μL) for 3 doses with 5-minute intervals
Study: NCT05662397
Drug: HST-1011
DrugBank: ST-101 (DB12621)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HST-1011 given orally
Study: NCT06752798
Drug: Trilaciclib + Cisplatin
Normalized name: Trilaciclib
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trilaciclib: 240 mg/m², intravenous infusion over 30 minutes, administered within 4 hours prior to each chemotherapy session. Cisplatin: 40 mg/m², intravenous infusion over 2-3 hours, once a week, for a total of 6-7 times.
Study: NCT06176352
Drug: Faricimab
Normalized name: Faricimab
DrugBank: Faricimab (DB15303)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Faricimab 6 mg intravitreal (IVT) injection on Day 1 with Q4W PRN treatment thereafter to Week 44. At Week 48, participants will attend a follow-up visit.
Study: NCT06176352
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab 0.5 mg intravitreal (IVT) injection on Day 1 with Q4W PRN treatment thereafter to Week 44. At Week 48, participants will attend a follow-up visit.
Study: NCT06311578
Drug: JNJ-87704916
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-87704916 will be administered as an intratumoral injection.
Study: NCT06311578
Drug: Cetrelimab
Normalized name: Cetrelimab
DrugBank: Cetrelimab (DB15421)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetrelimab will be administered.
Study: NCT06747728
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients were enrolled and given bevacizumab on days 1 and 15, administered by intravenous infusion at 5 mg/kg.
Study: NCT04802161
Drug: Liposome-encapsulated Daunorubicin-Cytarabine
Normalized name: DAUNORUBICIN/CYTARABINE
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04802161
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT06785298
Drug: Fexofenadine
Normalized name: Fexofenadine
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine is a second-generation antihistamine that does not penetrate the CNS and has the least CNS side effects among the second-generation antihistamines
Study: NCT06761417
Drug: Mitoxantrone liposome
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitoxantrone liposome: 16 mg/m\^2, d1; Each 21-day cycle was used for a total of 4-6 cycles.
Study: NCT06761417
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib: according to patient weight: 8mg/ day in patients \<35kg; 10mg/ day for patients with 35kg≤ patient weight ≤50kg; 12mg/ day for patients \> 50kg; d1-14; Each 21-day cycle was used for a total of 4-6 cycles.
Study: NCT05227612
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive two doses of psilocybin (10mg, 25mg).
Study: NCT06765928
Drug: selinexor in combination with venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: After allo-HSCT, intermediate-high risk MDS/AML patients are maintenanced with selinexor given in combination with venetoclax for 2 years
Study: NCT06420765
Drug: VX-150
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension for oral administration.
Study: NCT06420765
Drug: VX-548
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution or suspension for oral administration.
Study: NCT06420765
Drug: VX-993
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension for oral administration.
Study: NCT06749691
Drug: Liposomal Irinotecan and Apatinib
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Liposomal Irinotecan in Combination With Apatinib
Study: NCT06754267
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: BCL-2 inhibotor
Study: NCT06754267
Drug: Olverembatinib
Normalized name: Olverembatinib
DrugBank: HQP1351 (DB16185)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine kinase inhibitor
Study: NCT06754267
Drug: Predinisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucocorticoids
Study: NCT06767527
Drug: AK112
Normalized name: IMMUNOGLOBULIN G1 (240-ALANINE,241-ALANINE), ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR A) (HUMAN-MUS MUSCULUS MONOCLONAL AK112 .GAMMA.1-CHAIN) FUSION PROTEIN WITH PEPTIDE LINKER (GGGS)4 FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN PROGRAMMED CELL
DrugBank: Ivonescimab (DB18931)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK112 via intravenous (IV) infusion
Study: NCT06767527
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-Paclitaxel 100mg/m2 via IV infusion on Days 1, 8, and 15 of each 28-day cycle
Study: NCT05468320
Drug: Caplacizumab
Normalized name: caplacizumab
DrugBank: Caplacizumab (DB06081)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lyophilized powder for solution for injection.
Study: NCT06758544
Drug: Oncolytic virus VRT106
Normalized name: rubella virus
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRT106, IV
Study: NCT06769828
Drug: Ga-68-FAPI-46
Normalized name: Fapilavir
DrugBank: Favipiravir (DB12466)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Ga-68-FAPI-46 PET scan in colorectal cancer
Study: NCT06769698
Drug: FDC fianlimab+cemiplimab
Normalized name: cemiplimab
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fixed-Dose Combination (FDC) Administered per the protocol
Study: NCT06769698
Drug: Cemiplimab
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered per the protocol
Study: NCT06767566
Drug: Ketamine (Ketalar)
Normalized name: ketamine Injectable Solution [Ketalar]
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loading Dose: 0.18 mg/kg/hr x 1 hour; Maintenance Dose 0.05 mg/kg/hr x 11 hours
Study: NCT06762587
Drug: Baloxavir Marboxil
Normalized name: Baloxavir Marboxil
DrugBank: Baloxavir marboxil (DB13997)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Baloxavir marboxil will be administered on the first day following the close contact's enrollment in this study. Participants weighing ≤80 kg will receive 40 mg of baloxavir marboxil, while those weighing ≥80 kg will receive 80 mg.